In this issue:
64Cu-bis-PSMA vs 68Ga-PSMA PET/CT for prostate cancer detection
68Ga-PSMA PET/CT for equivocal or clinical suspicion of prostate cancer
Aglatimagene besadenovec with radiotherapy for localised prostate cancer
Pretreatment MRI as a prognostic factor after radical prostatectomy
SBRT + nivolumab and ipilimumab for mCRPC
Biochemical recurrence and late toxic events after radiation therapy
Maximum standardised PSMA uptake and risk of metastases
PSA density thresholds in risk-based MRI-directed diagnosis
Five-year outcomes after negative MRI or biopsy
Long-term outcomes of cribriformpositive and -negative cancer
Please login below to download this issue (PDF)